1th June, 2024, Beijing Multi drug and rifampicin resistant tuberculosis (MDR/RR-TB) still represents a serious threat to global public health. Treatment success rate of traditional long course regimen (≥18 month) for this disease lingers below 60%. While short course all oral Bedaquiline containing regimens currently recommended by the WHO, such as BPaL and BPaLM are not yet accessible for Chi...

21st May, Yichang, HubeiIn the wake of the International Day for Clinical Trials, 18-19th May, 2024, the national training workshop on TB clinical research methodology and practice as well as the Annual Conference of the China TB Clinical Trials Consortium (CTCTC) was successfully held in Yichang, Hubei province. This workshop was organized in concert by the Beijing Chest Hospital, Wuhan Pulmona...

5th March, 2024, Xiamen 2-3rd March, the fourth TB R&D cooperation international forum was successfully held in Xiamen, Fujian province. This forum has been a collaboration between the Innovation Alliance (IATB) and the Bill & Melinda Gates Foundation (BMGF) with the latter providing technical assistance and philanthropic donations. The past three forums addressed issues of pre-clinical ...

3rd March, 2024, XiamenNight 2nd March, Xiamen. The First Seminar on Tuberculosis International Public Health Market Development by China’s Innovative Diagnostic Companies was successfully held. This seminar was a collaboration between the Innovation Alliance (IATB) and Bill & Melinda Gates Foundation (BMGF) with the latter providing technical assistance and philanthropical donations. The a...